Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00843882 · OUTCOME

Proportion of Patients With Major Erythroid Response (MER) Among Those With Chromosome 5q31.1 Deletion

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia · Source last updated 2026-09-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
Assessed after completion of 16 weeks of treatment

What was measured

Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.

Analysis population: All patients with chromosome 5q31.1 deletion in arm A

Groups in this outcome

Arm A (Lenalidomide; Chromosome 5q31.1 Deletion)

Patients receive lenalidomide PO QD on days 1-21.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A (Lenalidomide; Chromosome 5q31.1 Deletion)38

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A (Lenalidomide; Chromosome 5q31.1 Deletion)0.632Not reported0.460.782Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.46
        upper Limit
        0.782
        value
        0.632
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    units
    Participants
description
Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive lenalidomide PO QD on days 1-21.
    id
    OG000
    title
    Arm A (Lenalidomide; Chromosome 5q31.1 Deletion)
param Type
NUMBER
population Description
All patients with chromosome 5q31.1 deletion in arm A
reporting Status
POSTED
time Frame
Assessed after completion of 16 weeks of treatment
title
Proportion of Patients With Major Erythroid Response (MER) Among Those With Chromosome 5q31.1 Deletion
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice